Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.
Marlies Wijsenbeen, MD, PhD
Advertisement
Pulmonary physician at the Erasmus University Medical Centre in Rotterdam
Articles by Marlies Wijsenbeen, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Clears Beta Bionics' Mint Insulin Patch Pump for Diabetes
2
Evolocumab Prevents Recurrent Cardiovascular Events Following MI or Stroke
3
Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer
4
FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis
5